Search Results - "Egeler, R M"

Acute GvHD: pathogenesis and classification by Ball, L M, Egeler, R M

“…Allogeneic hematopoietic SCT (HSCT) is an established treatment for some children with life-threatening hematological disease, immune deficiencies and inborn…”
Get full text

Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation by Bernardo, M E, Ball, L M, Cometa, A M, Roelofs, H, Zecca, M, Avanzini, M A, Bertaina, A, Vinti, L, Lankester, A, Maccario, R, Ringden, O, Le Blanc, K, Egeler, R M, Fibbe, W E, Locatelli, F

“…When compared with BMT, umbilical cord blood transplantation (UCBT) is associated with a lower rate of engraftment and delayed hematological/immunological…”
Get full text

Choroid plexus tumours by WOLFF, J. E. A, SAJEDI, M, BRANT, R, COPPES, M. J, EGELER, R. M

“…Choroid plexus tumours are rare epithelial brain tumours and limited information is available regarding their biology and the best treatment. A meta-analysis…”
Get full text

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways by Cleton-Jansen, A-M, Anninga, J K, Briaire-de Bruijn, I H, Romeo, S, Oosting, J, Egeler, R M, Gelderblom, H, Taminiau, A H M, Hogendoorn, P C W

“…Background: Osteosarcoma is the most prevalent primary malignant bone tumour in children and young adults, with poor survival in 40% of patients. To identify…”
Get full text

High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study by Bresters, D, van Gils, I C M, Kollen, W J W, Ball, L M, Oostdijk, W, van der Bom, J G, Egeler, R M

“…The aim of our study was to assess the cumulative incidence and severity (‘burden’) of late effects in a single-centre cohort of childhood haematopoietic stem…”
Get full text

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD by Jol-van der Zijde, C M, Bredius, R G M, Jansen-Hoogendijk, A M, Raaijmakers, S, Egeler, R M, Lankester, A C, van Tol, M J D

“…Anti-thymocyte globulin (ATG), raised in rabbits, is frequently used in allogeneic hematopoietic SCT (HSCT), to prevent graft rejection and acute GVHD. In…”
Get full text

Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience by SLATS, A. M, EGELER, R. M, VAN DER DOES-VAN DEN BERG, A, KORBIJN, C, HÄHLEN, K, KAMPS, W. A, VEERMAN, A. J. P, ZWAAN, C. M

“…We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid…”
Get full text

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation by Lankester, A C, Bierings, M B, van Wering, E R, Wijkhuijs, A J M, de Weger, R A, Wijnen, J T, Vossen, J M, Versluys, B, Egeler, R M, van Tol, M J D, Putter, H, Révész, T, van Dongen, J J M, van der Velden, V H J, Schilham, M W

“…Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT). A…”
Get full text

Parental stress and perceived vulnerability at 5 and 10 years after pediatric SCT by Vrijmoet-Wiersma, C M J, Egeler, R M, Koopman, H M, Bresters, D, Norberg, A L, Grootenhuis, M A

“…With the aim of assessing parental stress after SCT, 73 parents of children and adolescents who underwent SCT 5 or 10 years ago responded to questionnaires on…”
Get full text

Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation by MIANO, M, LABOPIN, M, PETERS, C, ORTEGA, J, VEYS, P, BORDIGONI, P, IORI, A. P, NIETHAMMER, D, ROCHA, V, DINI, G, HARTMANN, O, ANGELUCCI, E, CORNISH, J, GLUCKMAN, E, LOCATELLI, F, FISCHER, A, EGELER, R. M, OR, R

“…This paper describes the trends in haematopoietic stem cell transplantation (HSCT) activity for children in Europe over the last three decades. We analysed…”
Get full text

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity by ZWAVELING, J, BREDIUS, R. G. M, CREMERS, Sclm, BALL, L. M, LANKESTER, A. C, TEEPE-TWISS, I. M, EGELER, R. M, DEN HARTIGH, J, VOSSEN, J. M

“…We studied the pharmacokinetics of intravenous busulfan (Bu) in children in order to further optimize intravenous Bu dosing in relation to toxicity and…”
Get full text

How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more by HEEMSKERK, M. B. A, VAN WALRAVEN, S. M, DONKER, A. E, HOOGERBRUGGE, P. M, VAN ROOD, J. J, CLAAS, F. H. J, OUDSHOORN, M, CORNELISSEN, J. J, BARGE, R. M. Y, BREDIUS, R. G. M, EGELER, R. M, LIE, Jlwtj, REVESZ, T, SINTNICOLAAS, K, WULFFRAAT, N. M

“…Many patients do not reach haematopoietic stem cell transplantation. Shortage of unrelated donors (UDs) is still seen as the main cause. However, with a…”
Get full text

CsA exposure is associated with acute GVHD and relapse in children after SCT by Willemze, A J, Press, R R, Lankester, A C, Egeler, R M, den Hartigh, J, Vossen, J M

“…CsA is commonly used after haematological SCT (HSCT) as GVHD prophylaxis. In solid organ transplantation, area under the blood concentration vs time curve…”
Get full text

Patient reported outcomes in pediatric oncology practice: Suggestions for future usage by parents and pediatric oncologists by Schepers, S.A., Engelen, V.E., Haverman, L., Caron, H.N., Hoogerbrugge, P.M., Kaspers, G.J.L., Egeler, R.M., Grootenhuis, M.A.

“…Several studies in adults have shown patient reported outcomes (PROs) to be effective in enhancing patient‐physician communication and discussion of Health…”
Get full text

Clinical aspects of Langerhans cell histiocytosis by Aricò, M, Egeler, R M

“…Langerhans cell histiocytosis remains an enigmatic disease with protean manifestations. It may be self-limited in some, whereas in others, even intensive…”
Get more information

Differential In Situ Cytokine Profiles of Langerhans-Like Cells and T Cells in Langerhans Cell Histiocytosis: Abundant Expression of Cytokines Relevant to Disease and Treatment by Egeler, R. Maarten, Favara, Blaise E., van Meurs, Marjan, Laman, Jon D., Claassen, Eric

“…The pathogenesis of Langerhans cell histiocytosis (LCH) remains poorly understood. To further elucidate LCH pathogenesis, we analyzed the expression of 10…”
Get full text

Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature by LANKESTER, A. C, VISSER, L. F. A, HARTWIG, N. G, BREDIUS, R. G. M, GASPAR, H. B, VAN DER BURG, M, VAN TOL, M. J. D, GROSS, T. G, EGELER, R. M

“…X-linked lymphoproliferative disease (XLP) is a rare immunodeficiency caused by mutations in the signaling lymphocyte activating molecule-associated…”
Get full text

Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas by Anninga, J.K, van de Vijver, M.J, Cleton-Jansen, A.M, Kristel, P.M.P, Taminiau, A.H.M, Nooij, M, Egeler, R.M, Hogendoorn, P.C.W

“…The aim of our study was to determine whether or not the tyrosine kinase receptor, HER2 (also known as ErbB2/Her2/ neu), is overexpressed in human…”
Get full text

Significance of Amplified Fragment Length Polymorphism in Identification and Epidemiological Examination of Candida Species Colonization in Children Undergoing Allogeneic Stem Cell Transplantation by BALL, L. M, BES, M. A, THEELEN, B, BOEKHOUT, T, EGELER, R. M, KUIJPER, E. J

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group by Jöris, M M, Bierings, M B, Egeler, R M, Claas, F H J, van Rood, J J, Oudshoorn, M

“…To investigate whether all patients in need of an allogeneic hematopoietic SCT (HSCT) are offered one, we retrospectively investigated the policy for all…”
Get full text